_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
Partnered by:
Associate Partners:
My Account
Partnered by:
Associate Partners:
Partnered by:
Associate Partners:
BSE Live
Jan 25, 16:00Prev. Close
5033.80
Open Price
5059.65
Bid Price (Qty.)
5075.90 (253)
Offer Price (Qty.)
5085.00 (3)
NSE Live
Jan 25, 16:05Prev. Close
5036.90
Open Price
5042.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5082.40 (416)
| Nine Months Results of Dr Reddys Laboratories (in Rs. Cr.) | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 | |
| Net Sales/Income from operations | 8,972.70 | 7,858.30 | 6,826.00 | 7,324.70 | 7,867.00 | |
| Other Operating Income | 26.00 | 122.00 | 41.00 | 35.00 | 46.50 | |
| Total Income From Operations | 8,998.70 | 7,980.30 | 6,867.00 | 7,359.70 | 7,913.50 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,902.20 | 1,579.90 | 1,437.00 | 1,434.60 | 1,560.90 | |
| Purchase of Traded Goods | 891.10 | 632.10 | 457.00 | 502.90 | 483.70 | |
| Increase/Decrease in Stocks | -167.10 | -40.30 | -12.70 | -167.20 | -74.90 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 1,513.60 | 1,441.90 | 1,379.70 | 1,431.00 | 1,261.20 | |
| Depreciation | 596.90 | 576.40 | 584.10 | 545.50 | 468.30 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | 800.70 | 759.70 | 771.70 | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 2,510.10 | 2,503.60 | 1,801.80 | 1,963.90 | 1,877.90 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 1,751.90 | 1,286.70 | 419.40 | 889.30 | 1,564.70 | |
| Other Income | 615.80 | 165.70 | 130.90 | 533.20 | 226.30 | |
| P/L Before Int., Excpt. Items & Tax | 2,367.70 | 1,452.40 | 550.30 | 1,422.50 | 1,791.00 | |
| Interest | 36.00 | 48.10 | 48.70 | 41.40 | 49.50 | |
| P/L Before Exceptional Items & Tax | 2,331.70 | 1,404.30 | 501.60 | 1,381.10 | 1,741.50 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 2,331.70 | 1,404.30 | 501.60 | 1,381.10 | 1,741.50 | |
| Tax | -103.20 | 329.80 | 111.30 | 220.00 | 328.50 | |
| P/L After Tax from Ordinary Activities | 2,434.90 | 1,074.50 | 390.30 | 1,161.10 | 1,413.00 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 2,434.90 | 1,074.50 | 390.30 | 1,161.10 | 1,413.00 | |
| Equity Share Capital | 83.10 | 83.00 | 82.90 | 82.90 | 85.30 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 146.89 | 64.75 | 23.54 | 69.55 | 82.86 | |
| Diluted EPS | 146.62 | 64.67 | 23.49 | 69.38 | 82.60 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 146.89 | 64.75 | 23.54 | 69.55 | 82.86 | |
| Diluted EPS. | 146.62 | 64.67 | 23.49 | 69.38 | 82.60 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- |
29.10.2020
Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y
29.10.2020
Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y
28.10.2020
Dr Reddy's Labs Q2 profit falls 30% to Rs 762 crore, global generics business up 21%
29.08.2020
22.01.2021
18.01.2021
Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher
29.07.2020
Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%
14.10.2019
